top of page

Beat the Beast: Remdesivir - The New Corona Killer?

An interesting article on COVID-19 treatments by Nell Sloane.

Why Investors Are Hanging So Much Hope on Remdesivir: More than 20 publicly traded companies are working on evaluating drugs that could potentially treat the novel coronavirus disease. Several of those candidates come from well-known names like Bayer and Eli Lilly, but it's Gilead's remdesivir drug that investors are following most closely. Health experts say it's the drug furthest along in clinical studies and results from one of the company's late-stage trials is expected as soon as today. Keep in mind, two separate leaked reports about remdesivir trials over the last couple of weeks seem to have had broad market impacts. The first, showing remdesivir was highly effective in treating Covid-19 patients, came out on April 17, a day the Dow rallied over +700 points. The other, posted on April 23, said the drug didn't show any clinical benefit at all, which traders blamed for quashing a rally and a -5% decline in Gilead's stock. Gilead will also be releasing results from another of its late-stage trials in May which could coincide with results from the U.S National Institute of Allergy and Infectious Disease's (NIAID) own late-stage study of remdesivir. read more here



1 view0 comments

Recent Posts

See All

Good News On the Jobs Front

This jobs number should ease some recession fears, although next weeks CPI will be a key indicator as we all know. Payrolls were up 372,00 better than expected with the unemployment rate remains at 3.

More Products to Manage Risk

It is incredible the products the CME Group keep developing to efficiently manage risk. Coming in October they will be releasing products that lenders and other institutional financial market users wi

CME to Launch New Lumber Futures Contract

The CME in August will be introducing a new Lumber Futures Contract that is very beneficial to hedgers. Her are the highlights... New Lumber futures and options Launching on August 8* Th


bottom of page